- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
BridgeBio Pharma CEO Sells $2M in Stock
Neil Kumar sold over 28,000 shares, representing a 10.69% decrease in his position.
Published on Feb. 26, 2026
Got story updates? Submit your updates here. ›
BridgeBio Pharma CEO Neil Kumar sold 28,053 shares of the company's stock on February 19th for a total value of $2,002,703.67. The sale represented a 10.69% decrease in Kumar's position, leaving him with 234,451 shares valued at $16,737,456.89. The transaction was disclosed in a filing with the Securities & Exchange Commission.
Why it matters
Insider selling can sometimes signal a lack of confidence in a company's future prospects, though the reasons behind the sale are not always clear. As the CEO, Neil Kumar's stock transactions are closely watched by investors and analysts as an indicator of the company's direction.
The details
The shares were sold at an average price of $71.39. Following the transaction, Kumar still owns 234,451 shares in the company, which has a market cap of $12.82 billion. BridgeBio Pharma is a clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases and cancers.
- The shares were sold on Thursday, February 19th, 2026.
The players
Neil Kumar
The CEO of BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.
A clinical-stage biopharmaceutical company headquartered in Palo Alto, California that is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers.
The takeaway
Insider transactions, particularly by a company's CEO, can provide insights into management's views on the business's prospects. While the reasons behind this stock sale are not explicitly stated, it represents a notable decrease in the CEO's personal stake in the company.
